OTC: CLVLY - Clinuvel Pharmaceuticals Limited

Lønnsomhet i seks måneder: +2.63%
Sektor: Healthcare

Kampanjeplan Clinuvel Pharmaceuticals Limited

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).

Flere detaljer
The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

EBITDA 0.0168
EV/EBITDA 98.24
ISIN US1887691038
Industry Biotechnology
P/BV 29.78
P/E 93.89
P/S 54.84
Sector Health Care
Валюта usd
Валюта отчета usd
Выручка 0.031
Див.доход ао 0.3347
Дивиденд ао 0.0478
Сайт https://www.clinuvel.com
Цена ао 9.03
Число акций ао 0.05182 млрд
Prisendring per dag: 0% (9.75)
Prisendring per uke: +4.28% (9.35)
Prisendring per måned: -3.66% (10.12)
Prisendring over 3 måneder: -4.88% (10.25)
Prisendring over seks måneder: +2.63% (9.5)
Prisendring per år: -2.6% (10.01)
Prisendring over 3 år: -68.54% (30.99)
Prisendring over 5 år: -57.42% (22.9)
Prisendring siden begynnelsen av året: -5.06% (10.27)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 5.76 2
P/BV 2.5 6
P/E 14.26 8
EV/EBITDA 5.78 9
Total: 7.13

Effektivitet

Navn Betydning Karakter
ROA, % 15.42 5
ROE, % 17.55 5
Total: 7.33

Utbytte

Navn Betydning Karakter
Div yield, % 0.3467 0.88
DSI 1 10
Total: 3.85

Plikt

Navn Betydning Karakter
Debt/EBITDA 0.0156 10
Total: 10

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 170.49 10
Lønnsomhet Ebitda, % 313.79 10
Lønnsomhet EPS, % 111.63 10
Total: 9.4
Flere detaljer

Institusjoner Volum Dele, %
Trust For Professional Managers-PMC Diversified Equity Fund 4782 0.01



Veileder Stillingstittel Betaling Fødselsår
Dr. Philippe Jacques Wolgen M.B.A., M.D. CEO, MD & Director 1.86M 1963 (61 år)
Mr. Lachlan Hay Chief Operations Officer N/A
Mr. Malcolm Bull Head of Australian Operations & Investor Relations N/A
Dr. Rose Quadbeck-Diel Senior Vice President of Regulatory Affairs N/A
Dr. Azza Hamila Head of Quality Assurance & Drug Safety N/A
Dr. Dennis J. Wright BPharm, M.Sc., Ph.D. Chief Scientific Officer
Mr. Peter Vaughan Chief Financial Officer
Ms. Claire Newstead-Sinclair C.A. Company Secretary

Adresse: Australia, Melbourne. VIC, 535 Bourke Street - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.clinuvel.com